Aura Biosciences, Inc. Net Fee Amt
Aura Biosciences, Inc. (AURA) had Net Fee Amt of $1.08 thousand as of 2026-09-01, per its S-8 filed 2026-09-01.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-09-01
- 2026-09-01: Net Fee Amt $1.08K.
- 2026-08-07: Net Fee Amt $69.05K.
- 2026-05-19: Net Fee Amt $3.50K.
- 2026-05-04: Net Fee Amt $6.89K.
| Period end | Net Fee Amt |
|---|---|
| 2026-09-01 | $1.08K S-8 · filed 2026-09-01 |
| 2026-08-07 | $69.05K S-3 · filed 2026-08-11 |
| 2026-05-19 | $3.50K S-8 · filed 2026-05-19 |
| 2026-05-04 | $6.89K S-3MEF · filed 2026-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |